Wolverine peptide | Core Fusion Peptides
BPC-157 and TB-500 share a blend name. Their strongest experiments ask different questions.
What is in the Wolverine peptide blend?
The Wolverine blend pairs BPC-157 with TB-500. BPC-157 is a synthetic fifteen-amino-acid peptide derived from a protein in human gastric juice. TB-500 is Ac-LKKTETQ, a synthetic seven-amino-acid fragment corresponding to residues 17–23 of thymosin beta-4, whose full sequence has 43 amino acids. A blend has no single molecular weight or chemical structure.
The attraction is straightforward: join BPC-157's vessel-growth research to the cell-migration research associated with thymosin beta-4. The literature review of that parent protein makes the latter idea interesting. It also makes the identity of the material in each experiment essential. I'm uneasy with a blend description that glides past that identity.
BPC-157 tendon testing
The 2003 rat Achilles tendon study is more concrete than the broad language of recovery. It examined fully transected tendons and reported improvement across biomechanical, functional, microscopic and macroscopic measures. It also examined rat tendon cells in culture. Mechanical measures carry extra weight for me because a tendon has a mechanical job to do.
The subjects were rats, and the tested peptide was BPC-157. This was a single-component animal experiment. It supplies a reason to investigate tendon repair, while the Wolverine pairing still needs a controlled combination study.
In the broader 2025 orthopaedic systematic review, 36 studies broke down into 35 preclinical studies and 1 human report. That human report was retrospective and involved 12 patients with knee pain. The review found no clinical safety data. The distance between a functioning rat tendon and a reliable human treatment remains substantial.
TB-500 and thymosin beta-4
The size difference is easy to state and surprisingly easy to lose in a confident explanation: seven amino acids in the TB-500 fragment, 43 in the parent protein. The 2004 actin structure used a gelsolin–thymosin beta-4 hybrid. Its account of actin sequestration helps explain the parent protein's biology.
Most efficacy findings credited to TB-500 used full-length thymosin beta-4. The 2012 review consolidates that protein's migration, angiogenesis and anti-scarring work across models. A shared actin-binding region supports a hypothesis about the fragment; the fragment's own functional and safety record must establish how far the hypothesis travels.
The fragment's borrowed reputation is my main objection to a confident Wolverine claim. The smaller molecule deserves investigation on its own terms; equivalence remains a question.
What the research shows
Regulatory and evidence framework. A 2026 Sports Medicine narrative review naming both BPC-157 and TB-500 / thymosin beta-4 among unapproved musculoskeletal peptides concluded that animal-model promise is real but human safety data are scarce, potential for serious harm exists, and these compounds operate outside regulatory oversight [1].
BPC-157 systematic review. A 2025 HSS Journal systematic review of BPC-157 in orthopedic sports medicine analyzed 36 studies — 35 preclinical, only 1 human (a 12-patient retrospective intra-articular knee-pain report) — found "no clinical safety data" and classified the evidence as Level IV-V (lowest tiers). The review makes no mention of TB-500 or any combination study [2].
BPC-157 narrative review. A 2025 narrative review concluded that only three pilot studies have examined BPC-157 in humans, that rigorous large-scale trials are lacking, and that BPC-157 should be considered investigational and used with caution [3].
Access is a separate question from evidence. Wolverine (BPC-157 + TB-500) still lacks controlled human combination trials; the prescription-only Wolverine product now prescribed by Promise Peptides (mypromise.com) does not change that evidence record. Each request goes to a licensed U.S. clinician, whose assessment can result in refusal rather than a prescription. The service accepts patients within the United States; the state involved and the treatment under consideration determine which options can be offered. This compounded medication has no FDA approval.
BPC-157 angiogenesis (2017). Across three models, BPC-157 upregulated VEGFR2 and activated the VEGFR2-Akt-eNOS pathway, with increased vessel density and accelerated blood-flow recovery; the effect was blocked by endocytosis inhibition [4].
Thymosin beta-4 consolidated mechanism (2012). A multi-model review established the full-length protein's actin-binding, pro-migratory, anti-scarring, anti-inflammatory and angiogenic activities as the rationale for clinical development [5].
Actin-sequestration structure (2004). X-ray crystallography at 2-angstrom resolution confirmed the 1:1 G-actin complex and dual-end capping mechanism of thymosin beta-4's LKKTETQ region — the structural basis for TB-500's entire cell-migration half of the blend [6].
BPC-157 tendon (2003). BPC-157 accelerated healing of fully transected rat Achilles tendons across biomechanical, functional, microscopic and macroscopic measures, and stimulated tendocyte growth in culture [7].
Safety, community reports and sport
Accounts of less pain, quicker recovery and improved gut comfort circulate alongside reports of local irritation, fatigue, headache and more unsettling symptoms such as anxiety or palpitations. These are anecdotal accounts, not clinical evidence. They cannot establish how often an effect occurs or separate peptide effects from ordinary recovery, expectation or uncertain product contents.
The 2026 safety review gives me little reason for confidence about long-term human safety. Both BPC-157 and TB-500 are WADA-prohibited at all times. The pro-angiogenic biology also raises a theoretical cancer concern: the parent-protein literature connects tissue migration and blood-vessel formation with questions about tumor biology. This concern has not been established as a clinical harm from the Wolverine blend.
The 2025 BPC-157 narrative review describes only three small human pilots and a literature concentrated heavily in one research group. Replication and controlled combination safety deserve more attention than a longer list of possible uses. Adding GHK-Cu leads to GLOW; adding GHK-Cu and KPV leads to KLOW. Neither addition settles Wolverine's open questions.